Furthest along
26 approved
16 in Phase 3
Drugs
97
in active trials · 229 in all
Trials
228 active
714 since 2021
Drugs97
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 18 Nov 2026soonPhase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 18 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Neuromyelitis Optica Spectrum Disorder, NMOSD and 4 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 19 Nov 2026soonPhase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 19 Nov 2026 · Phase 4 trial completes | ||||
| Also tested for | Severe Hemophilia A, Moderate Hemophilia A and 2 more | ||||
| Open drug page | |||||
ALK inhibitor |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung and 3 more | ||||
| Open drug page | |||||
Programmed death receptor-1 blocking antibody |
Approved | 30 Nov 2026soonPhase 3 trial completes | |||
| How it works | Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer and 34 more | ||||
| Open drug page | |||||
Vascular endothelial growth factor inhibitor |
Approved | 30 Nov 2026soonPhase 3 trial completes | |||
| How it works | Blocks VEGF | ||||
| Next date | 30 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Cancer, Hepatocellular Carcinoma and 8 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer and 2 more | ||||
| Open drug page | |||||
Tyrosine kinase inhibitor |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Solid Tumors and 18 more | ||||
| Open drug page | |||||
BRAF inhibitor |
Approved | 30 Nov 2026soonPhase 2 trial completes | |||
| Next date | 30 Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer, Cancer | ||||
| Open drug page | |||||
Bispecific CD20-directed CD3 T cell engager |
Approved | 28 Dec 2026Phase 1/2 trial completes | |||
| How it works | An antibody that marks B cells (a type of immune cell) for destruction | ||||
| Next date | 28 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Lymphoma, Non-Hodgkin's Lymphoma and 6 more | ||||
| Open drug page | |||||
CD20-directed cytolytic antibody |
Approved | 28 Dec 2026Phase 1/2 trial completes | |||
| How it works | An antibody that marks B cells (a type of immune cell) for destruction | ||||
| Next date | 28 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Lupus Nephritis, Lymphoma and 9 more | ||||
| Open drug page | |||||
Interleukin-6 receptor antagonist |
Approved | 28 Dec 2026Phase 1/2 trial completes | |||
| How it works | Blocks interleukin-6 | ||||
| Next date | 28 Dec 2026 · Phase 1/2 trial completes | ||||
| Also tested for | Multiple Myeloma, Lymphoma and 15 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 26 Jan 2027Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 26 Jan 2027 · Phase 4 trial completes | ||||
| Also tested for | Diabetic Macular Edema, Neovascular Age-related Macular Degeneration (nAMD) | ||||
| Open drug page | |||||
Vascular endothelial growth factor inhibitor |
Approved | 4 Feb 2027Phase 3 trial completes | |||
| How it works | Blocks VEGF | ||||
| Next date | 4 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Neovascular Age-related Macular Degeneration, Diabetic Macular Edema and 2 more | ||||
| Open drug page | |||||
HER2/neu receptor antagonist |
Approved | 28 Mar 2027Phase 3 trial completes | |||
| How it works | Blocks HER2 | ||||
| Next date | 28 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Neoplasm Metastasis, Solid Tumors and 2 more | ||||
| Open drug page | |||||
HER2/neu receptor antagonist |
Approved | 28 Mar 2027Phase 3 trial completes | |||
| How it works | Blocks HER2 | ||||
| Next date | 28 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Solid Tumors, Breast Cancer and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 31 Mar 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 31 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Neoplasm Metastasis, Solid Tumors and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 18 Apr 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 18 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome | ||||
| Open drug page | |||||
Polymerase acidic endonuclease inhibitor |
Approved | 30 Apr 2027Phase 3 trial completes | |||
| Next date | 30 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Influenza, Influenza, Human and 2 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 3 May 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 3 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Metastatic Breast Cancer and 12 more | ||||
| Open drug page | |||||
— |
Approved | 3 May 2027Phase 3 trial completes | |||
| Next date | 3 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer, Locally Advanced or Metastatic Breast Cancer and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About
- No active trial
- 132 other drugs
- SEC filings
- None: it does not file with the US SEC
- Registry names
- 3 names in ClinicalTrials.gov Hoffmann-La Roche
Genentech, Inc.
Chugai Pharmaceutical - Sources
- ClinicalTrials.gov updated 16 Nov 2026 Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev